Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as an A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an A2A receptor antagonist.

Abstract: Disclosed herein are 5 or 8-substituted imidazo [1, 5-a] pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo [1, 5-a] pyridines, processes for the preparation thereof and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo [1, 5-a] pyridines that can be useful for inhibiting indoleamine 2, 3-dioxygenase and/or tryptophane 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: A test device and method for top-of-the-line corrosion (TLC) of a high-temperature high-pressure wet gas pipeline. The device mainly includes: a metal top cap, a metal reaction cylinder, a first thermometer, a second thermometer, a plastic transparent measuring cylinder, a condensed water collection tube, an atomic spectrometer, a third thermometer, a rubber seal cover, a condensate droplet, a threaded hole, a condensation chamber, a pipeline sample, a temperature measuring hole, and a 30-degree tilt angle. The device and method can effectively simulate TLC of a wet gas pipeline under a high-temperature high-pressure environment. The device and method can test the high-temperature high-pressure TLC of the wet gas pipeline under different temperature differences (between a surface temperature of the pipeline and a gas temperature) and various corrosion media.

Abstract: Disclosed herein are 5 or 8-substituted imidazo[1,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[1,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo[1,5-a]pyridines that can be useful for inhibiting indoleamine 2,3-dioxygenase and/or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.

Abstract: Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

Abstract: Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

Abstract: A mobile device includes a sensing unit configured to determine whether the stylus pen is separated from the mobile device; a communication unit configured to receive a control signal including a first control signal and a second control signal from the stylus pen separated from the mobile device; and a controller configured to operate in a first control mode for performing an operation of an application being executed on the mobile device. The controller performs a first operation of the application in response to the first control signal, and performs a second operation of the application in response to the second control signal.

Abstract: Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.

Abstract: Disclosed herein are 5 or 8-substituted imidazo [1, 5-a] pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo [1, 5-a] pyridines, processes for the preparation thereof and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo [1, 5-a] pyridines that can be useful for inhibiting indoleamine 2, 3-dioxygenase and/or tryptophane 2, 3-dioxygenase and for treating diseases or disorders mediated thereby.

Abstract: Disclosed are a mobile device and a method of operating the mobile device. A mobile device according to an embodiment includes a sensing unit configured to determine whether a stylus pen is separated from the mobile device, a communication unit configured to receive a control signal from the stylus pen separated from the mobile device, and a controller configured to operate in a first control mode for performing at least one operation of an application being executed on the mobile device, in response to the control signal.

Abstract: Disclosed herein are 5 or 8-substituted imidazo[1,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[1,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo[1,5-a]pyridines that can be useful for inhibiting indoleamine 2,3-dioxygenase and/or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.

Abstract: An electric motor comprising a gearbox housing containing a gearbox, a sump, a first-stage shaft rotatably mounted in the gearbox housing, and a rotatably-mounted motor shaft coupled to the first-stage shaft of the gearbox. The first-stage shaft has an internal passageway defined along the longitudinal axis of the first-stage shaft and extending between opposite first and second ends thereof. At the second end the internal passageway communicates with the sump. The rotatably-mounted motor shaft is coupled to the first end of the first-stage shaft. The motor shaft has an internal passageway defined along the longitudinal axis of the motor shaft and extending between opposite first and second ends thereof. At the second end thereof, the internal passageway of the motor shaft communicates with the internal passageway of the first-stage shaft at the first end thereof.

Abstract: The invention relates to 5-(((1R,1aS,6bR)-1-(6-(trifluoromethyl)-1H-benzo [d] imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy)-3,4-dihydro-1, 8-naphthyridin-2 (1H)-one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.

Abstract: Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.

Abstract: Disclosed herein are 5 or 8-substituted imidazo[1,5-a]pyridines and pharmaceutical compositions comprising at least one such 5 or 8-substituted imidazo[1,5-a]pyridines, processes for the preparation thereof, and the use thereof in therapy. Disclosed herein are certain 5 or 8-substituted imidazo[1,5-a]pyridines that can be useful for inhibiting indoleamine 2,3-dioxygenase and/or tryptophane 2,3-dioxygenase and for treating diseases or disorders mediated thereby.

Abstract: Provided are certain fused tricyclic urea compounds and salts thereof, compositions thereof, and methods of use therefor.

Abstract: Provided are certain fused tricyclic compounds and salts thereof, compositions thereof and methods of use therefor.